Artiva Biotherapeutics, Inc. (ARTV) Live Share Price, Invest From India

Artiva Biotherapeutics, Inc. Stock Performance

as on September 24, 2026 at 3:11 am IST

Day's Low
Day's High
$7.52
Day's Price Range
$8.12
$7.58
0.79%
Downside
7.12%
Upside
52 Week's Low
52 Week's High
$2.52
52-Week Price Range
$14.53
$7.58
66.75%
Downside
91.69%
Upside

Artiva Biotherapeutics, Inc. share price movements today

Previous Close: $8.09
Open: $8.12
Volume: 146.6K
Market Cap: $382.8M
Day's Low - High: $7.52 - $8.12
52 Week Low - High: $2.52 - $14.53

Artiva Biotherapeutics, Inc. Historical Returns

1 Month Return: -25.98 %
3 Month Return: -17.45 %
1 Year Return: + 212.36 %
3 Year Return: 0 %
5 Year Return: 0 %

Artiva Biotherapeutics, Inc. Stock Fundamentals & Key Indicators

Check Artiva Biotherapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$382.8M

EPS (TTM)

-3.31

Dividend Yield

0.00%

PE Ratio (TTM)

-2.37

Industry PE ratio

-6.68

PEG Ratio

-0.716000264885793

Return On Equity TTM

-53.86%

Artiva Biotherapeutics, Inc. Stock Valuation

Track how Artiva Biotherapeutics, Inc. P/E has moved over time to understand its valuation trends.

Artiva Biotherapeutics, Inc. in the last 5 years

Overview
Trends

Lowest (-10.09x)

December 31, 2023

Industry (-6.68x)

December 31, 2025

Today (-1.25x)

December 31, 2025

Highest (-1.25x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: -1.25x

Artiva Biotherapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Artiva Biotherapeutics, Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Artiva Biotherapeutics, Inc.	StrongBuy	$382.8M	NA	-2.37	0.00%	0.00%
Moderna	Neutral	$69.0B	-59.84%	-21.67	-12.57%	0.00%
Vertex Pharmaceuticals	StrongBuy	$129.4B	178.24%	29.49	86.04%	0.00%
Regeneron	Buy	$80.8B	24.34%	19.2	84.86%	0.46%

Stock Returns calculator for Artiva Biotherapeutics, Inc. Stock including INR - Dollar returns

The Artiva Biotherapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Artiva Biotherapeutics, Inc. investment value today

Current value as on today

₹3,15,508

Returns

₹2,15,508

(+215.51%)

Returns from Artiva Biotherapeutics, Inc. Stock

₹1,92,664 (+192.66%)

Dollar Impact

₹22,844 (+22.84%)

Analyst Recommendation on Artiva Biotherapeutics, Inc. Stock

Based on 3 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 3 analysts, 100% of analysts recommend a 'BUY' rating for Artiva Biotherapeutics, Inc.. Average target price of $38

Indian Investors' Interest in Artiva Biotherapeutics, Inc. Stock

Search interest for Artiva Biotherapeutics, Inc. Stock has decreased by -63% in the last 30 days, reflecting a downward trend in search activity.

Time period: August 24, 2026 to September 23, 2026

Change:-63% versus previous 30 day period

Artiva Biotherapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Revenue	0	-	-	-	-	-	-	-	-	-
Gross Profit	0	-	-	-	-	-	-	-	0	-
Operating Income	-14	-16	-18	-18	-22	-22	-22	-21	-24	-26
EBITDA	-13	-17	-16	-8	-19	-20	-20	-20	-22	-23
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	1
Income Before Tax	-13	-17	-17	-9	-20	-21	-21	-20	-23	-25
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-13	-17	-17	-9	-20	-21	-21	-20	-23	-25
Net Profit Margin	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Artiva Biotherapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	2	4	33	0	-
Gross Profit	-	2	4	33	0	-2
Operating Income	-18	-53	-59	-30	-67	-90
EBITDA	-17	-71	-57	-25	-56	-81
Interest Expense	0	-	-	-	-	-
Depreciation	0	0	1	2	2	2
Income Before Tax	-17	-71	-58	-27	-58	-83
Income Tax Expense	-	-	0	0	-	-
Net Income	-17	-71	-58	-27	-58	-83
Net Profit Margin	0.00%	100.00%	100.00%	100.00%	100.00%	0.00%

Artiva Biotherapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Net Income	-13	-17	-17	-16	-20	-21	-21	-20	-23	-48
Operating Cash Flow	-15	-13	-11	-14	-19	-22	-19	-14	-20	-41
Investing Cash Flow	9	1	-130	0	9	21	16	16	15	32
Financing Cash Flow	-	-1	163	0	0	0	0	0	0	283
Change in Cash	-5	-13	21	-15	-9	-1	-2	1	-5	274

Artiva Biotherapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-17	-71	-58	-28	-65	-83
Operating Cash Flow	-13	-15	-50	-47	-55	-76
Investing Cash Flow	0	-1	-6	-25	-120	63
Financing Cash Flow	37	152	-1	24	162	0
Change in Cash	23	135	-58	-49	-13	-13

Mutual Funds that own Artiva Biotherapeutics, Inc. Stock

Check out the Mutual Funds with significant holdings in Artiva Biotherapeutics, Inc..

Funds	Holdings	Shares Held
VANGUARD INDEX FUNDS	0.424801%	207686
Franklin Strategic Series	0.394498%	192871
Fidelity Concord Street Trust	0.185018%	90456
Bridgeway Funds, Inc.	0.071589%	35000
Nationwide Mutual Funds	0.042339%	20700

See all

Global Institutional Holdings in Artiva Biotherapeutics, Inc.

Funds	Holdings
Peter Kolchinsky	36.73%
Andreas Halvorsen	5.33%
Stephen A. Schwarzman	4.92%
Vanguard	2.3%
VANGUARD INDEX FUNDS	0.42%

See all

Insights on Artiva Biotherapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 1 year, Moderna, Inc. Common Stock has given 607.9% return, outperforming this stock by 395.5%
NEGATIVE IMPACT
Price Dip
In the last 7 days, ARTV stock has moved down by -5.9%

About Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.

Organisation	Artiva Biotherapeutics, Inc.
Headquarters	5505 Morehouse Drive, San Diego, CA, 92121, US
Industry	Biotechnology
CEO	Fred Aslan
E-voting on shares	Click here to vote

Key Management of Artiva Biotherapeutics, Inc.

Name	Title
Dr. Fred Aslan M.D.	CEO, Principal Financial & Accounting Officer and Director
Ms. Jennifer Kinsbruner Bush Esq., J.D.	Chief Operating Officer
Dr. Peter Flynn Ph.D.	Co-Founder & Strategic Advisor
Dr. Heather Raymon Ph.D.	Senior Vice President of Research & Early Development
Dr. David Moriarty Ph.D.	Senior VP of Clinical Operations
Dr. Gines Diego Miralles M.D.	President and Head of Research & Development
Mr. Christopher P. Horan	Chief Technical Operations Officer
Mr. Andrew Cronauer	VP, General Counsel & Corporate Secretary
Dr. Nicholas Veomett Ph.D.	Vice President of Corporate Development
Mr. Benjamin Dewees	Senior Vice President of Regulatory Affairs

FAQs

What is Artiva Biotherapeutics, Inc. share price today?

Artiva Biotherapeutics, Inc. share price today is $7.58 as on September 23, 2026 at 9:41 pm IST. Artiva Biotherapeutics, Inc. share today touched a day high of $8.12 and a low of $7.52.

What is the 52 week high and 52 week low for Artiva Biotherapeutics, Inc. share?

Artiva Biotherapeutics, Inc. share touched a 52 week high of $14.53 on April 20, 2026 and a 52 week low of $2.52 on September 24, 2025. Artiva Biotherapeutics, Inc. stock price today i.e. September 23, 2026 at 9:41 pm IST is trending at $7.58,which is 47.83% down from its 52 week high and 200.79% up from its 52 week low.

What is Artiva Biotherapeutics, Inc.'s market capitalisation today?

Artiva Biotherapeutics, Inc. market capitalisation is $0.00T as on September 23, 2026 at 9:41 pm IST.

How to invest in Artiva Biotherapeutics, Inc. Stock (ARTV) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Artiva Biotherapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Artiva Biotherapeutics, Inc. Shares that will get you 0.1979 shares as per Artiva Biotherapeutics, Inc. share price of $7.58 per share as on September 23, 2026 at 9:41 pm IST.

What is the minimum amount required to buy Artiva Biotherapeutics, Inc. Stock (ARTV) from India?

Indian investors can start investing in Artiva Biotherapeutics, Inc. (ARTV) shares with as little as ₹95.74 or $1 (as of September 23, 2026 at 9:41 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹957.40 in Artiva Biotherapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on September 23, 2026 at 9:41 pm IST). Based on Artiva Biotherapeutics, Inc. share’s latest price of $7.58 as on September 23, 2026 at 9:41 pm IST, you will get 1.3193 shares of Artiva Biotherapeutics, Inc.. Learn more about fractional shares .